Literature DB >> 2891696

Characterization of the cyclic AMP-independent actions of somatostatin in GH cells. II. An increase in potassium conductance initiates somatostatin-induced inhibition of prolactin secretion.

B D Koch1, A Schonbrunn.   

Abstract

The neuropeptide somatostatin inhibits prolactin release from GH4C1 pituitary cells via two mechanisms, inhibition of stimulated adenylate cyclase activity and an undefined cAMP-independent process. Somatostatin also hyperpolarizes GH4C1 cells and reduces their intracellular free Ca2+ concentration ([Ca2+]i) in a cAMP-independent manner. To determine whether these ionic changes were involved in the cAMP-independent mechanism by which somatostatin inhibited secretion, changes in cAMP levels were prevented from having any biological consequences by performing experiments in the presence of a maximal concentration of a cAMP analog. Under these conditions, inhibition of prolactin release by somatostatin required a transmembrane concentration gradient for K+ but not one for either Na+ or Cl-. However, elimination of the outward K+ gradient did not prevent somatostatin inhibition of vasoactive intestinal peptide-stimulated hormone release. Therefore, somatostatin's cAMP-mediated mechanism does not require a K+ gradient, whereas its cAMP-independent inhibition of secretion appears to result from a change in K+ conductance. Consistent with this conclusion, membrane hyperpolarization with gramicidin (1 microgram/ml) mimicked somatostatin inhibition of prolactin release. In addition, the K+ channel blocker tetrabutylammonium prevented the effects of somatostatin on the membrane potential, the [Ca2+]i and hormone secretion. Nonetheless, a K+ gradient was not sufficient for somatostatin action. Even in the presence of a normal K+ gradient, somatostatin was only able to inhibit prolactin release when the extracellular Ca2+ concentration was at least twice the [Ca2+]i. Furthermore, the calcium channel blocker, nifedipine (10 microM), which prevents the action of somatostatin to reduce the [Ca2+]i, specifically blocked inhibition of prolactin release via somatostatin's cAMP-independent mechanisms. Therefore, a decrease in Ca2+ influx through voltage-dependent Ca2+ channels produces both the fall in [Ca2+]i and inhibition of hormone secretion in response to somatostatin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2891696

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Molecular cloning and functional expression of a brain-specific somatostatin receptor.

Authors:  J F Bruno; Y Xu; J Song; M Berelowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

2.  Tissue-specific distribution of cross-linked somatostatin receptor proteins in the rat.

Authors:  C B Srikant; K K Murthy; Y C Patel
Journal:  Biochem J       Date:  1992-03-01       Impact factor: 3.857

Review 3.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

4.  Regulation of Somatostatin Receptor 2 Trafficking by C-Tail Motifs and the Retromer.

Authors:  Courtney Olsen; Kimiya Memarzadeh; Arzu Ulu; Heather S Carr; Andrew J Bean; Jeffrey A Frost
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

5.  Somatostatin inhibits vasopressin-stimulated phosphoinositide hydrolysis and influx of extracellular calcium in clonal hamster beta (HIT) cells.

Authors:  S B Richardson; T Laya; M Gibson; N Eyler; M Van Ooy
Journal:  Biochem J       Date:  1992-12-15       Impact factor: 3.857

Review 6.  Illuminating somatostatin analog action at neuroendocrine tumor receptors.

Authors:  Jean Claude Reubi; Agnes Schonbrunn
Journal:  Trends Pharmacol Sci       Date:  2013-10-31       Impact factor: 14.819

7.  Inhibition by somatostatin of amylase secretion induced by calcium and cyclic AMP in rat pancreatic acini.

Authors:  H Ohnishi; T Mine; I Kojima
Journal:  Biochem J       Date:  1994-12-01       Impact factor: 3.857

8.  The PDZ Domain Protein SYNJ2BP Regulates GRK-Dependent Sst2A Phosphorylation and Downstream MAPK Signaling.

Authors:  Heather S Carr; Jeffrey T Chang; Jeffrey A Frost
Journal:  Endocrinology       Date:  2021-02-01       Impact factor: 4.736

9.  Real-Time Signaling Assays Demonstrate Somatostatin Agonist Bias for Ion Channel Regulation in Somatotroph Tumor Cells.

Authors:  Melissa Rodriguez; Jeffrey A Frost; Agnes Schonbrunn
Journal:  J Endocr Soc       Date:  2018-06-14

10.  The human brain somatostatin interactome: SST binds selectively to P-type family ATPases.

Authors:  Michael Solarski; Declan Williams; Mohadeseh Mehrabian; Hansen Wang; Holger Wille; Gerold Schmitt-Ulms
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.